Objective: No definitive peripheral biological marker has yet been found to correlate with Alzheimer's disease (AD). This study investigated the role of macrocytosis as a marker which could significantly improve our u n d e r s tanding of AD in the Down's syndrome (DS) population.
Introduction
The identification of specific genetic or biological markers associated with Alzheimer's disease (AD) would be a tremendous advance in the research and clinical management of this form of dementia. It would improve the clinical diagnostic accuracy (use of clinical diagnosis alone can lead to a misdiagnosis in 20%-30% of cases in the non-LD (learning disability) population, 1 aid early detection, improve quality of treatment trials, increase our knowledge of the pathogenesis of the disorder and determine if AD is a specific brain disease or a generalised system disorder. Further, as a diagnosis of AD is often made by exclusion of other disorders; such a biological measure would be a 'positive' indicator of AD. To date no such measure is available but an ideal test should be (a) easily accessible (eg. from urine, blood, saliva), (b) readily discriminate AD from other forms of intellectual decline (eg. depressive pseudodementia; age-associated cognitive decline), (c) have good sensitivity and specificity for AD and (d) be cost effective.
A number of peripheral red blood cell measures possibly associated with AD in the non-learning disability (LD) population have been proposed (see Table 1 ). If, as is generally accepted, AD in adults with Down's syndrome (DS) is a similar disease process as seen in the non-LD population, it would seem reasonable to assume any identified peripheral measure should show some degree of abnormality in both populations. Comparable research into biological measures associated with AD in the non-LD population has not been carried out in the DS population. The reasons for this include (i) problems with ethical committee approval and the obtaining of informed consent (ii) the available population of DS adults with AD for research is relatively small when compared to the number of AD subjects available in the non-LD population and (iii) the accurate and early diagnosis of AD in adults with DS remains difficult.
Changes in red cell morphology as a measure for AD were first proposed by Goodall et al 2 , 3 when they noticed abnormally shaped red blood cells in non-LD adults with AD. Th e authors examined the red blood cells in 50 patients with AD (age range 58-95 years, mean age of subjects 81.0 years) along with cells from 100 age and sex matched non-LD control patients. Fourteen per cent of the AD group had abnormalities as compared to 5% of the controls. This was s tatistically significant at the 5% level. One patient with AD had been known to have abnormalities several years before a diagnosis of AD was made. The authors were unsure of the cause of the distortion in shape of the red blood cells but suggested that abnormalities were secondary to cell membrane dysfunction. Such an association has not been established in the field of AD in the non-LD population.
Abnormalities in the morphology of red blood cells are known to occur in the DS population; particularly macrocytosis (increase in MCV above normal limits) and it remains possible that changes in red cell structure could be a measure for AD in the DS population. Eastham and Jancar 4, 5 in two articles reported macrocytosis (mean MCV 102.5+/-7. 87fl) in 92 DS adults on anticonvulsant medication and later in 33 DS adults not on anticonvulsants (mean MCV 96.3+/-3 . 79fl). Both values were significantly above the accepted upper limit of the normal range for their laboratory (95fl). The authors had discussed the possibility of macrocytosis being a measure of accelerated ageing.
Hewitt et al 6 confirmed the findings by Eastham and J a n c a r 4 , 5 of an association between macrocytosis and DS when they investigated findings in 23 hospital patients aged over 50 years with DS. Mean corpuscular volume for the group as a whole was found to be at the upper range of normal (mean 95.4fl; upper limit 96fl). It was above this limit for 11 patients. The authors also investigated the hypothesis raised by Eastham and Jancar that macrocytosis was a measure of accelerated ageing. 5 Patients were regularly assessed for mental age using The Stanford Binet Intelligence Scale 7 and therefore deterioration in mental function could be determined. For nine patients with intellectual deterioration the MCV was greater than the mean sample result. Macrocytosis was found in only two non-deteriorated patients. Although a significant association between intellectual decline and macrocytosis was found the deterioration was not reported to be due to the presence of dementia per se as the study did not assess for the presence or absence of AD.
Further evidence supporting an association between macrocytosis and intellectual decline in adults with DS was provided by Lansdall-Welfare and Hewitt. 8 The research e r s reviewed MCV results over time for 23 DS patients living in an institution for people with LD. The authors found that the mean MCV for those with intellectual deterioration was 100.23fl (range 92 to 106) compared with 95.14fl (range 91-103.2) for those without intellectual deterioration. Th e difference was significant (P < 0.005). Again subjects had not been assessed for presence or absence of dementia, s u ch that a direct link between macrocytosis and AD could not be made.
The cause of macrocytosis in adults with DS was specifically investigated by several researchers. The commonest cause in the non-LD population is nutritional deficiency but for people with Down's syndrome macrocytosis occurs independent of anaemia, vitamin B12 or folate deficiency.
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Further, Wachtel and Pueschel demonstrated that the actual cause is a reduced life span of red blood cells.
1 0 The authors investigated MCV in 61 adults with DS (range 17-66 years; mean age 30 years) and in LD controls. The mean MCV for the group was 99.1fl (range 90 -1 07fl). For those patients that were tested for red blood cell survival time (n = 10), the time was found to be shorter than that for non-LD controls. Th e findings indicated accelerated red blood cell ageing.
There was now reasonable evidence supporting an association between macrocytosis and DS, particularly for persons with intellectual deterioration. This was not due to dietary deficiency and appeared to reflect a reduction in the life span of circulating red blood cells. The question still remained whether the association was between macrocytosis and AD in older adults with DS or between macrocytosis and ageing per se. To date, studies had not differentiated between subjects with and without AD. Without doing so it was not possible to determine if macrocytosis could be a specific peripheral measure for AD in this population.
Prasher undertook such an investigation in a large crosssectional study. 12 Findings were reported for 147 adults of a sample of 201 adults assessed for dementia in Alzheimer's disease using DCR-10 criteria. 1 3 Mean age for the study sample was 54.1 years (age range 39 -72 years). The mean MCV value for the 147 subjects was 99.28 fl (range 77. 5 -116fl). The normal upper limit being 98.0fl. Seventy individuals had MCV values above this upper limit (> 98.0fl). No statistically significant correlation was found between mean MCV and age (Pearson's product-moment coefficient 0 . 041, P = 0.62). Sixty-six subjects had neither AD nor macrocytosis, 54 did not have AD but did have macrocytosis, 10 subjects had AD but no macrocytosis and 17 had both AD and macrocytosis. A borderline statistically significant association was found between macrocytosis and AD. These findings suggested that macrocytosis had the potential to be a peripheral measure for AD.
Prasher went on to investigate serial MCV changes in adults with DS with and without AD. 1 1 Seventeen adults were age-sex matched in each group. Alzheimer's disease was diagnosed according to DCR-10 criteria. 1 3 Mean corpuscular volume was measured at Time 0 and again one year later for all subjects. There was borderline statistical significance at Time 0 between the two groups which became sta t i s t i c a l l y significant one year later (Mann-Whitney U 2.13, P = 0.03). A significant increase in the MCV value as compared to a baseline value prior to the onset of AD was proposed as a possible measure of AD.
To investigate further the possible association between macrocytosis and AD in the DS population, this study was u n d e r taken to correlate longitudinal changes in MCV levels with deterioration in AD over a five year study period.
Methods
One-hundred and fifty adults with DS were recruited into this study. These were individuals of the original 201 subjects who were participating in the West Midlands Ageing Study and who were still available to participate. 1 4 D e m o g r a p h i c d a ta for each person including age, gender, karyotyping for DS, severity of LD, previous psychiatric or medical history and medication intake were collected. Severity of premorbid LD was assessed by (i) review of previously reported intelligence tests, (ii) previous level of functioning as determined by review of medical notes, from carer interview and from the m e n tal state examination of the individual. Severity of LD was During the study period for the subjects who were still alive, reassessment of their physical health was underta k e n on an annual basis. Carers were interviewed to elicit any evidence, during the year prior to being seen, of any significant medical condition and to elicit any symptoms suggestive of a new ongoing medical illness. Previous hospital records and, where necessa r y, general practitioner records had been reviewed during the first study year to highlight any conditions requiring specific monitoring. For those individuals where, from the carer interview there was evidence of a previously unreported physical illness, a further physical e xamination was undertaken as part of their annual review. As part of the general health assessment, subjects seen each year underwent annual (where compliant) venepuncture for routine haematological (including B12 and folate levels), b i o chemical (including plasma glucose level) and thyroid screening.
An annual psychiatric assessment was undertaken by using Part 1 Section H of the CA MDEX sch e d u l e , 17 s ta n d a r d mental state examination of subjects, and completion of the ICD-10 Symptom Checklist for Mental Disorders. 1 6 A s recommended by the International research community 1 8 a l l available information was assessed to determine the presence of mental disorder according to ICD-10 criteria 1 5 and in particular Dementia in Alzheimer's disease. 13 Annual mean corpuscular volume (MCV) levels were measured by the technique described by Ty ck o . 19 This technique uses the simultaneous measurement of laser light that is scattered at two different angular intervals, which eliminates the adverse effect of variation in cellular haemoglobin concentration on the determination of cell volume. During the study period all samples were analysed by the same laboratory and by the same machine. All samples were analysed within five hours of being taken to prevent introduction of artificial error.
The statistical analysis used allowed for missing data . Correlation between the longitudinal findings for MCV levels and AD were determined. All data were entered and analysed using Minitab (version 13). Findings for MCV levels were entered after each annual assessment but not analysed until after the final year data had been entered. Where possible observer bias was reduced by, for example, making the DCR -10 diagnosis for AD after each annual assessment and therefore independent of the measured variables.
Results (a) Demographics
One hundred and fifty adults with DS participated in this s t u d y, of which 83 (55%) were male and 67 (45%) were female. The mean age of the total sample population at year one was 44.0 years (standard deviation At the start of the study, the majority of the 150 individuals were living in the community with 60 (40%) living in their family homes, 57 living in hostels/group homes (38%) and 33 (22%) resident in hospital. For the 60 individuals living in their family home, the mean age was 39. The physical and psychiatric clinical assessments were available for all 150 subjects at year one and year two of the five-year study period. Only 146 subjects were seen at year three because four had died, 139 at year four when 11 had died and 131 at year five, by which time 19 had died.
(b) Alzheimer's disease status
Forty-four individuals had a diagnosis of 'Dementia in Alzheimer's disease' made at some data point during the fiveyear study period according to DCR-10 criteria. 1 3 Th i s diagnosis was independent of information obtained from the antemortem measures. For a diagnosis of AD other possible causes of dementia must be excluded. In this study sa m p l e no subject presented with dementia due to cerebrovascular disease, HIV disease, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, vitamin B12 or folic acid deficiency, hypercalcaemia, alcohol or drug abuse. Of the clinically significant disorders which could impair intellectual functioning, definite hypothyroidism (low thyrox i n e , raised thyroid stimulating hormone) was found in 21 subjects and depression (DCR-10 diagnosis) in 15 subjects.
The mean age for the 44 AD subjects was 53.2 years (SD 8.46, range 36-74 years). Seventeen (39%) were males and 27 (61%) females. At the start of the study of the 44 AD subjects, 13 people (30%) were living in their family home, 23 (52%) in a community group home and 8 (18%) were resident in the hospital. Of the subjects with AD, a premorbid level of LD of moderate impairment was the commonest 34 individuals (78%), with mild LD in five cases (11%) and severe in five (11%). This reflects the distribution of severity of LD seen in the sample group. With respect to duration of the dementing process, 24 (54%) of the 44 subjects had AD for at least three years but only five (11%) throughout the study period. Fifteen (34%) individuals of the AD group died during the study period.
(c) Mean corpuscular volume (MCV)
One hundred and forty subjects had at least one MC V result available for analysis during the five-year period. In tota l 512 data cells were available for analysis (subjects x time period). Results were available for 116 subjects at year one, 98 subjects at year two, 102 at year three, 96 at year four and for 100 subjects at year five. Poor compliance with venepuncture and death of subjects during the study period were the principal reasons for missing results.
The mean MCV value for the total sample for whom results were available was 97.33fl (SD 5.27; range 77. 50 -1 1 5 . 90 ) . This was at the upper limit of the normal range for the non-LD population (normal range 78-99fl). For subjects who had no significant medical disorder, an association was found between MCV and age of subjects (Pearson's correlation coefficient; P<0.05) but on further examination this association was found to be confined to males only (r = 0.22; p < 0.05).
The sample population for whom MCV values were available was sub-divided into those with no evidence of AD during the study period (non dementia group; n = 388 ) , those that developed dementia during the study period (new dementia group; n = 62) and those that had dementia throughout the study period (persistent dementia group; N = 62).
Analysis of variance (ANOVA) of the data was undertaken with subjects as a nested random factor within the three dementia groups. This form of data analysis controls for patient variability, for different subjects contributing to the d a ta set at different years and variation between dementia groups. Across the groups there was a significant difference in mean MCV scores (P = 0.002). The non-demented group had an adjusted mean MCV of 96 . Confounding factors other than onset of AD which could cause an increased level of MCV were investigated. Age and gender (above) have been shown to have an effect on MCV. Separate analysis by gender was, therefore, undertaken. Th i s demonstrated that for non-demented males in this study, a mean MCV of 96 . 44 (SEM 0.21) was found and for males with persistent dementia the mean MCV was 99.35 (SEM 0.51); a statistically significant difference (P < 0.001). Fo r non-demented females a mean MCV of 97.5 (SEM 0.36) was found and for females with persistent dementia a value of 102.6 (SEM 0.79). Again a statistically significant difference (P < 0.001). Mean corpuscular volume being greater for females than males.
Using one-way analysis of variance with subjects as the grouping factor and time as a co-variate for the persistent dementia group no statistically significant association was found with severity or duration of the dementing process (P = 0.384 and P = 0.522 respectively). This would suggest that MCV increases as a person with DS develops AD but does not continue to increase further as the dementing process progresses in severity and/or duration. Figure 1 shows the longitudinal mean MCV values for the non dementia group and the persistent dementia group over the 5-year study period. Values for the latter group being consistently greater. For males and females to assess a suitable cut-off point on MCV for separating the non dementia group from the persistent dementia group sensitivity, specif i c i t y, positive predictive values (PPV) and negative predictive values (NPV) were calculated at a range of cut-off MC V levels (see Table 2 ) and the Receiver Operating Characteristic Curves were plotted (see Figure 2) .
From the MCV cut-off levels for sensitivity and specificity ( Table 2 ) and from the Receiver Operating Characteristic Curves ( Figure 2 ) the most accurate test in terms of sensitivity and specificity for AD in male adults with DS would be a MCV level greater than 97fl and for females a level of 99fl. This would give a sensitivity of 70% for males and of 78% for females and specificity of 59% for males and of 60% for females.
For both sexes, however, low PPV results illustrate that a single measurement of MCV is too inaccurate to be a valid test for AD in adults with DS. For male adults with DS a value of MCV greater than 97fl and for females a value greater than 99fl will correctly identify seven to eight out of 10 DS subjects with AD but lead to four out of 10 being unnecessarily assessed for dementia.
Serum vitamin B12 and/or folate deficiency can lead to an increase in MC V. Such deficiencies can be the result in demented subjects of poor nutritional intake or side-effects of anticonvulsant medication (phenytoin) for seizures. However, from the detailed clinical data available during the five years which was collected to make a DCR-10 13 diagnosis of AD, no statistical significant difference in serum B12 levels was found between demented and non-demented DS subjects (t-test; t-value = 0.1; P > 0.05). A mean serum B12 level of 416ng/L (SD 155; range 17 5 -878 n g /L) for non-AD subjects and a mean serum level of 423ng/L (SD 121; range 308 -6 2 3 n g /L) for AD subjects was found. The normal range for serum B12 being 160-1100ng/L.
Similarly no statistical significant difference was found between the two groups for serum folate level (t-test; t-value = 0.18; P > 0.05). The mean serum folate level was 6.2ug/l ( SD 3.4; range 1.9-19.5ug/L) for non-AD subjects and a mean serum folate level of 5.9ug/l (SD 3.5; range 3.3-11.9ug/l) for AD subjects. Normal range for serum folate is 1.5-20.0ug/l. Down's syndrome subjects with AD were found, therefore, to have the same vitamin status as well non-demented DS subjects. No subject in this study was found to be vita m i n B12 or folate deficient. None of the AD subjects was prescribed phenytoin. The principal anticonvulsants used were carbamazepine, sodium valproate and diazepam; none of which are reported to cause macrocytosis.
Other common causes of a raised MCV are alcoholism, chronic hepatitis, blood malignancy, ch e m o t h e r a p y, pernicious anaemia and hypothyroidism. A review of the medical information for the AD cases found none of these possible causes present. An association between AD and an increase in MCV does appear to be present for the DS population.
Discussion
Methodological difficulties (eg. small sample size, validity of AD diagnosis) apply to research investigating a possible association between macrocytosis and AD in the DS population. However, from the literature review it is apparent little interest has been shown previously, both in the non-LD and DS population regarding macrocytosis as a possible peripheral measure of AD.
There is reasonable evidence from previous studies supporting an association between intellectual decline and macrocytosis in older adults with DS . 5, 6, 10 Findings from this five-year prospective study further supports previously published work by the author highlighting an association between a raised MCV and AD in the DS population. 11, 12 The findings from this study demonstrate that a raised MCV is significantly associated with AD in the DS population; a higher value for females than for males. Mean corpuscular volume could, therefore, be an important antemortem measure for AD in this population. However, a single MCV reading has little diagnostic validity and on its own cannot be used as an accurate test for AD.
A reading above 97fl for males and above 99fl for females could be used as an adjunct to the clinical assessment for AD in adults with DS but cannot be used to replace the sta ndard assessment. A MCV result above the upper limit of normal (> 99fl) in a DS person with suspected AD may support the diagnosis. This study suggests that for all DS adults suspected to be suffering from dementia a blood test for MCV should be undertaken and used with caution to aid the clinical diagnosis of AD.
It remains possible that the findings do not reflect a direct association between a raised MCV and AD in the DS population but has resulted for some other reason. For example , individuals with dementia have poor food intake and can develop vitamin B12 or folate deficiency which could lead to anaemia and macrocytosis. In this study this is unlikely to be the cause of the raised MCV has none of the AD subjects had vitamin B12 or folate deficiency and no statistical significant difference was found in serum vitamin B12 and serum folate levels for subjects with and without AD.
From the detailed medical information and medical assessments collected on all subjects during the five years, other causes of a raised MCV were also excluded. None of the AD subjects had a history of alcoholism, chronic hepatitis, a blood dyscrasia, untreated hypothyroidism or were ta k i n g medication which could result in a raised MC V. It is unlikely the findings are an artefact but further research also investi- The underlying physiological mechanisms leading to an association between a raised MCV and AD remain to be fully investigated. Several mechanisms have been suggested: i) Increased activity of superoxide dismutase (SOD), resulting in overproduction of hydrogen peroxide and hydrox y l radicals which disrupt cellular functioning and subsequently leading to intellectual impairment and changes in MCV. 20 ii) Abnormalities in red cell membrane. Bosman et al 21 investigated red cell membrane function in 31 adults with DS . Twelve had no signs of clinical dementia (mean age 27 +/-4 years), 10 with early signs of clinical dementia (mean age 54+/-6 years) and nine subjects with advanced dementia (mean age 62+/-6 years). Abnormalities in erythrocyteprotein IgG and enhanced breakdown of anion membrane transporter band 3 were found in the demented subjects. Th e authors hypothesised that such findings were associated with altered red blood cell ageing leading to subsequent reduced lifespan of red blood cells and greater numbers of large red blood cells in the blood. iii) Increased activity of cellular enzymes adenosine deaminase and glucose-6-phosphatase dehydrogenase leading to red cell dysfunction and abnormalities in cell size and impairment of intellectual functioning. 22 Macrocytosis may be a sign of premature ageing, a condition previously associated with Down's syndrome. 2 3 O ka m o t o et al 2 4 have previously reported macrocytosis as part of a 'premature ageing syndrome'. It remains possible that AD in adults with DS is a 'symptom' of premature ageing and an increased MCV is also a reflection of this. This may explain why an association between a raised MCV and AD has not been reported in the non-LD population.
A raised MCV is the first peripheral marker to be consistently shown to be associated with AD in the DS population. As such this may further improve our understanding of AD and lead to improvement in diagnosis and possibly in treatment. The measurement of MCV is a simple procedure, of limited expense, and available in all geographical areas. The author is not aware of similar longitudinal analysis of MC V and clinical AD but further research by independent researchers is recommended.
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